Cytokinetics assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Cytokinetics (CYTK) with an Overweight rating and $67 price target The firm continues to believe that MAPLE-HCM study has the potential to play a meaningful role in the adoption of aficamten as the company hopes it can drive greater physician familiarity and prescribing outside of Centers of Excellence, the analyst tells investors in a research note. Ahead of the September 26 PDUFA, Cytokinetics management has submitted its 120-day safety update to FDA with an additional 10 months of safety data from FOREST-HCM trial and expects to have a mid-cycle meeting with the FDA in March, the firm adds.